Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 18/20 | 0.69 |
| ▸ | CASP2 | P42575 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28922786 | 1.00 | EPHX1 (0.69) | EPHX1CASP2EPHX2ALDH1A1HTT | |
| SCHEMBL5166886 | 0.98 | EPHX1 (0.65) | EPHX1CASP2EPHX2ALDH1A1HTT | |
| SCHEMBL10867933 | 0.92 | EPHX1 (0.59) | EPHX1EPHX2 | |
| SCHEMBL966938 | 0.83 | — | — | |
| SCHEMBL25225195 | 0.83 | EPHX1 (1.00) | EPHX1CASP2EPHX2 | |
| SCHEMBL25227881 | 0.83 | EPHX1 (1.00) | EPHX1CASP2EPHX2 | |
| SCHEMBL25276783 | 0.83 | EPHX1 (1.00) | EPHX1CASP2EPHX2 | |
| SCHEMBL25229277 | 0.83 | EPHX1 (1.00) | EPHX1CASP2EPHX2 | |
| SCHEMBL25270721 | 0.83 | EPHX1 (1.00) | EPHX1CASP2EPHX2 | |
| SCHEMBL25228721 | 0.83 | EPHX1 (1.00) | EPHX1CASP2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7867992-B2 | such as 1-Cyclopropyl-N-(2,4-dichlorobenzyl)-6-fluoro-8-methoxy-7-[3-methyl-4-(2-{[(methylamino)carbonyl]amino}-2-oxoethyl)piperazin-1-yl]-4-oxo-1,4-dihydroquinoline-3-carboxamide, used for the treatment and/or prophylaxis of viral diseases or infections, particularly against cytomegaloviruses | AICURIS GMBH & CO. KG (DE) | 2011-01-11 | — | — | US | disclosed |
| US-20070293478-A1 | Substituted quinolones | BAYER HEALTHCARE AG (DE) | 2007-12-20 | — | — | US | disclosed |
| EP-1768973-B1 | SUBSTITUTED QUINOLONES | AICURIS GMBH & CO KG (DE) | 2007-12-05 | — | — | EP | disclosed |
| EP-1768973-A1 | SUBSTITUTED QUINOLONES | AiCuris GmbH & Co. KG (DE) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006008046-A1 | SUBSTITUTED QUINOLONES | AICURIS GMBH & CO. KG (DE) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293478-A1 | Substituted quinolones | IRF3, TPMT, NQO2 | EPHX1 1620/4885CASP2 1229/4885EPHX2 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.